Healthcare
Biotechnology
Technology
Acorda Therapeutics
$10.769876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.26 (-2.36%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ACOR and other stocks, options, ETFs, and crypto commission-free!
About
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. Read More The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
CEO
Employees
474
Headquarters
Ardsley, New York
Founded
1995
Market Cap
523.14M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
799.52K
High Today
$11.01
Low Today
$10.68
Open Price
$10.93
Volume
288.64K
52 Week High
$36.35
52 Week Low
$9.58
Collections
Healthcare
Biotechnology
Technology
Health
Therapy
US
North America
News
Yahoo FinanceMay 9
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their portfolios in smaller cap stocks. We have been receiving ind...
TradingNewsNowMay 9
Current Trend: Acorda Therapeutics (NASDAQ: ACOR)
Acorda Therapeutics is in the biotechnology industry and is part of the healthcare sector. The company CEO is Ron Cohen. Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development and commercialization of novel therapies for the treatment of neurological disorders. Previous Intraday Trading Performance: The ACOR stock showed a previous change of 1.03% with an open at 11.57 and a close of 11.75. It reached an intraday high of 11.97 and a low of 11.41. SeekingA...
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Acorda Therapeutics Inc NASDAQ/NGS:ACOR View full report here! Summary ETFs holding this stock are seeing positive inflows Bearish sentiment is moderate Economic output in this company's sector is expanding Bearish sentiment Short interest | Neutral Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among inves...
Price Paid on Robinhood
29% Lower
Right Now
52 Week Low
$9.58
Average Price Paid
$15.11
52 Week High
$36.35
Earnings
-$0.94
-$0.16
$0.62
$1.40
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, Pre-Market